Kontoghiorghes G.J.

Kontoghiorghes G.J. refers to the research entity and institute led by George J. Kontoghiorghes, a pioneer in the field of iron metabolism and chelation therapy. The organization is best known for the invention and development of Deferiprone (L1), the first orally active iron-chelating drug used to treat iron overload in thalassemia patients. Based in Limassol, Cyprus, the institute operates as the Postgraduate Research Institute of Science, Technology, Environment and Medicine (PRI). Its research focuses on the design, synthesis, and clinical evaluation of novel iron chelators for various indications, including neurodegenerative diseases and oncology. The entity conducts independent clinical trials and collaborates with international academic centers to expand the therapeutic applications of chelation technology.